No evidence for epigenetic inactivation of fumarate hydratase in leiomyomas and leiomyosarcomas
| Autor: | Julia A. Bridge, Michelle D. Garrett, Richard S. Houlston, Hayley E. Spendlove, Cyril Fisher, Nassera S. Banu, Isaac Manyonda, Karen Barker, Janet Shipley |
|---|---|
| Rok vydání: | 2006 |
| Předmět: |
Adult
Leiomyosarcoma Cancer Research Pathology medicine.medical_specialty Context (language use) Biology medicine.disease_cause Epigenesis Genetic Fumarate Hydratase Leiomyomatosis Germline mutation medicine Animals Humans Epigenetics Mutation Leiomyoma Middle Aged medicine.disease female genital diseases and pregnancy complications body regions Oncology Immunoglobulin G Fumarase Uterine Neoplasms Myometrium Female Rabbits |
| Zdroj: | Cancer Letters. 235:136-140 |
| ISSN: | 0304-3835 |
| DOI: | 10.1016/j.canlet.2005.04.017 |
| Popis: | Germline mutations in Fumarate Hydratase (FH) cause the development of leiomyomas and leiomyosarcomas in the syndromes Multiple Cutaneous and Uterine Leiomyomata (MCUL1) and Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC). There is little evidence, however, that FH mutation plays a role in the development of sporadic leiomyomas or leiomyosarcomas. Such observations do not, however, exclude a role for FH in tumour development outside the context of MCUL1/HLRCC, as it is possible that FH expression could be silenced by epigenetic mechanisms. To explore this possibility we have developed a highly specific antibody to FH and analysed a series of forty-five fresh-frozen uterine leiomyomas and nine leiomyosarcomas for FH expression. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect